Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.glandpharma.com | |
Market Cap | 30,055.55 Cr. | |
Enterprise Value(EV) | 28,141.17 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 39.99 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 45.63 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.15 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 515.97 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 3.53 | Calculated using Price: 1,823.50 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 16.47 Cr. | 164,710,523 Shares |
FaceValue | 1 | |
About Gland Pharma Ltd. | ||
The company was incorporated as Gland Pharma Private Limited, a private limited company, at Hyderabad under the Companies Act, 1956 on March 20, 1978 and was granted the certificate of incorporation by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of the company was changed to Gland Pharma Limited pursuant to a special resolution passed by the shareholders of the Company on December 5, 1994, and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act, 1956. |
1 Day |
|
+0.66% |
1 Week |
|
+7.62% |
1 Month |
|
+0.57% |
3 Month |
|
-5.95% |
6 Month |
|
+10.55% |
1 Year |
|
+45.83% |
2 Year |
|
-42.77% |
5 Year |
|
|
10 Year |
|
4 years | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 21.29 | 20.97 | 18.61 | 10.34 | |
Return on Capital Employed (%) | 27.39 | 28 | 24.85 | 14.04 | |
Return on Assets (%) | 18.91 | 18.84 | 16.91 | 9.4 |
Particulars | 5 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 3,646 | 5,903 | 7,158 | 7,959 | 8,307 | |
Non Curr. Liab. | 81 | 80 | 94 | 90 | 406 | |
Curr. Liab. | 359 | 513 | 582 | 729 | 1,536 | |
Minority Int. | ||||||
Equity & Liab. | 4,086 | 6,496 | 7,834 | 8,778 | 10,248 | |
Non Curr. Assets | 1,240 | 1,372 | 1,982 | 1,877 | 4,277 | |
Curr. Assets | 2,846 | 5,124 | 5,852 | 6,901 | 5,971 | |
Misc. Exp. not W/O | ||||||
Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,248 |
Particulars | 5 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 2,633 | 3,463 | 4,401 | 3,525 | 4,912 | |
Other Income | 139 | 135 | 224 | 240 | 167 | |
Total Income | 2,772 | 3,598 | 4,625 | 3,765 | 5,079 | |
Total Expenditure | -1,678 | -2,161 | -2,891 | -2,612 | -3,769 | |
PBIDT | 1,095 | 1,437 | 1,734 | 1,153 | 1,310 | |
Interest | -7 | -3 | -5 | -7 | -18 | |
Depreciation | -95 | -99 | -110 | -147 | -290 | |
Taxation | -220 | -338 | -407 | -274 | -287 | |
Exceptional Items | 55 | -56 | ||||
PAT | 773 | 997 | 1,212 | 781 | 659 | |
Minority Interest | ||||||
Share Associate | ||||||
Other Related Items | ||||||
Consolidated Net Profit | 773 | 997 | 1,212 | 781 | 659 | |
Adjusted EPS | 50 | 61 | 74 | 47 | 40 |
Particulars | 4 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 701 | 605 | 791 | 364 | |
Cash Fr. Inv. | -766 | -1,524 | -1,003 | 1,208 | |
Cash Fr. Finan. | -7 | 1,238 | 35 | 15 | |
Net Change | -72 | 319 | -177 | 1,587 | |
Cash & Cash Eqvt | 170 | 492 | 319 | 1,909 |
Tue, 26 Mar 2024
Closure of Trading Window Trading Window of the Company will be closed w.e.f 27.03.2024 until 48 hours of declaration of Audited Financial results for the Quarter and Financial Year ended 31.03.2024 |
Mon, 25 Mar 2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Allotment of 2 400 Equity Shares on exercise of ESOP |
Mon, 25 Mar 2024
Announcement under Regulation 30 (LODR)-Change in Management Changes among Senior Management Personnel of the Company |
Wed, 27 Mar 2024 |
Close Crossing Last Week High |
Closing Above Previous High |
Close Above Last Week High |
High Increase in 1 Year |
Closing Near 100 SMA |